Photon Energy Earnings Call Transcripts
Fiscal Year 2025
-
Q4 2025 saw a 29.7% revenue decline and negative EBITDA, driven by asset disposals, regulatory impacts, and a major provision for a Polish TSO dispute. Liquidity is strained, with delayed bond coupon payments and ongoing asset sales to improve cash flow.
-
Q3 2025 saw revenue growth driven by technology trading and new energy, but electricity generation declined due to Romanian regulatory issues. EBITDA rose on asset sales, while impairments and liquidity challenges persisted. Management maintains full-year guidance and focuses on asset disposals, cost cuts, and refinancing.
-
Q2 saw modest revenue growth, driven by technology trading, while electricity generation revenues declined due to asset disposals and temporary shutdowns. Profitability was mixed across segments, with strong gains in technology and engineering, but losses in new energy. 2025 revenue is expected to exceed €110 million.
-
Best Q1 in three years with 27% revenue growth, strong electricity generation and technology performance, and improved EBITDA. Portfolio reshaped by asset sales and new projects; PFAS remediation and technology segments poised for further growth.
Fiscal Year 2024
-
Q4 2024 saw strong revenue growth and major portfolio shifts, but regulatory changes in Romania and Hungary weighed on profitability and asset values. New energy and engineering segments performed well, and the company is prioritizing financial improvement in 2025 to support bond refinancing.
-
Q3 saw strong EBITDA growth and new plant commissioning, but regulatory changes in Romania and the Czech Republic, along with project delays, led to reduced full-year guidance. The company is restructuring its technology trading and focusing on growth in O&M and energy storage.
-
Strong growth in generation and capacity drove higher EBITDA margins and improved cash flow, despite currency translation losses. Expansion into South Africa and robust EPC activity support a positive outlook, with full-year guidance reaffirmed.